TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00004635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Injections of Goserelin once a month for six months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
Study: NCT03650556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
Description: Ablation procedure for Persistent AF
Study: NCT00398918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: zonisamide (100 mg)one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT00723580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
Study: NCT02037022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment Package (PRT-P)
Study: NCT02125968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interactive video game
Description: short- and medium-term therapeutic effects

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: therapeutic exercise
Description: short- and medium-term therapeutic effects
Study: NCT03421535

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeper Stretch
Description: Internal Range of motion of dominant shoulder

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opposite SI joint Stretch
Description: Internal range of motion of dominant shoulder
Study: NCT02122458

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mild-gain hearing aids with high-frequency emphasis over 6-months
Description: open-fit hearing aids with mild amplification in the high frequencies.
Study: NCT03707678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP-DPI
Description: FP will be administered using Diskus inhaler with dosing strengths of 500, 250, 100, 50 µg twice daily per actuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eDairy
Description: Subjects will record all the alerts indicative of worsening of asthma in eDairy.
Study: NCT02764632

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital facilitation
Study: NCT02046031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgolides Meglumine Injection
Description: 25 mg, ivdrip, once.
Study: NCT02029404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tibial nerve group
Description: After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tibial peroneal nerve group
Description: After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump
Study: NCT04065477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-based cognitive rehabilitation (CBCR)
Description: Program designed to improve strategic cognitive domains (e.g., complex attention, working memory)
Study: NCT02404155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Study: NCT01815892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Withdrawal of furosemide
Description: The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide administration
Description: The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
Study: NCT03246880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: per oral for 12weeks after 2\~4weeks run-in period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Description: per oral for 12weeks after 2\~4weeks run-in period
Study: NCT02766855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine
Description: Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
Study: NCT03109457

Intervention type: OTHER
Intervention: oral squamous cell carcinoma
Description: Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.

Intervention type: OTHER
Intervention: oral squamous cell carcinoma
Description: Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
Study: NCT03483701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
Study: NCT02006511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incisional Neg Pressure Wound Therapy (Prevena™)
Description: Negative pressure wound therapy dressing applied over closed surgical incision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care wound therapy
Description: Gauze type dressing.
Study: NCT01788488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of procalcitonin as biomarker to guide therapy
Study: NCT02432742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Perlane
Description: Intradermal injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Intradermal injection
Study: NCT03707678

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: eDairy
Description: Subjects will record all the alerts indicative of worsening of asthma in eDairy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACQ-6
Description: ACQ-6 will include six questions which enquire about the frequency and/or severity of symptoms. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/limitation) scale.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ACQ-6
Description: ACQ-6 will include six questions which enquire about the frequency and/or severity of symptoms. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/limitation) scale.
Study: NCT00440414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Description: Erlotinib at the dose of 150 mg orally once a day continually until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta)
Description: Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
Study: NCT04234607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT01814644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRIMM Intervention
Description: Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Individual assessment, lifestyle counseling
Study: NCT04234607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is a cell cycle-specific antitumor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is a cell cycle-specific antitumor drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide is a cell cycle-specific antitumor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is cell cycle nonspecific antitumor drug
Study: NCT00857142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxymorphone hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opana
Study: NCT04234607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is cell cycle nonspecific antitumor drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is cell cycle nonspecific antitumor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450（blank）
Description: Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQB2450（blank）
Description: Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anlotinib（blank)
Description: Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
Study: NCT03913988

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lucid Dream
Description: Lucid dream techniques are a set of strategies to induce the ability to obtain conscious awareness during the dream state and include mental suggestions before sleep.
Study: NCT00635895

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymph Drainage Therapy and Connective Tissue Massage
Description: The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymph Drainage Therapy and Connective Tissue Massage
Description: The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
Study: NCT03913988

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lucid Dream
Description: Lucid dream techniques are a set of strategies to induce the ability to obtain conscious awareness during the dream state and include mental suggestions before sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Reduction
Description: Stress reduction techniques are a set of strategies designed to reduce anxiety and include meditation and guided imagery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Techniques
Description: Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Techniques
Description: Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Techniques
Description: Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.
Study: NCT04477889

Intervention type: OTHER
Intervention: Treatment for COVID-19
Description: Patients treated for COVID-19
Study: NCT02559258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg epsi-gam or placebo (6:2)
Description: administered as a single intravenous infusion on Day 1, infused over 30 minutes
Study: NCT00943137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Chemotherapy will be one of the following:~1. de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~2. FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~3. Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.
Study: NCT04252079

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular Repair of Juxtarenal Aortic Aneurysm
Description: 1. History taking and clinical examination.~2. Preoperative Imaging~   CTA is the cross-sectional imaging modality of choice.~3. Preoperative evaluation~   a-Renal evaluation~   b_ cardiac evaluation C-Pulmonary evaluation~4. Surgical techniques~   1. Anesthesia The use of general anesthesia due to the duration of the procedures and the necessity to control patient breathing to allow precise imaging and accurate device deployment.~  2. Intra operative imaging A hybrid operating room with high-quality fixed imaging is needed for the performance of FEVAR.~C-Device delivery and deployment all FEVAR procedures begin with access of the femoral arteries by either open or percutaneous technique.
Study: NCT00661856

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein
Description: 25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: 25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
Study: NCT02559258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg epsi-gam or placebo (6:2)
Description: administered as a single intravenous infusion on Day 1 infused over 30 minutes
Study: NCT00661856

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy protein
Description: 25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
Study: NCT03356756

Intervention type: DIAGNOSTIC_TEST
Intervention: simultaneous combined 18F-FDG PET and cardiac MRI imaging
Description: Patients will undergo a research study performed with an integrated whole-body PET/MRI imaging system designed for simultaneous PET and MRI acquisition, immediately after standard of care PET/CT exam.
Study: NCT01506258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of Stem Cells
Description: IV infusion of autologous stem cells within the first 48 hours after birth.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Observation
Description: Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
Study: NCT01957774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-18
Description: THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01497431

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02559258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg epsi-gam or placebo (6:2)
Description: administered as a single intravenous infusion on Day 1 infused over 30 minutes
Study: NCT01497431

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02559258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/kg epsi-gam or placebo (6:2)
Description: administered as a single intravenous infusion on Day 1 infused over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg epsi-gam or placebo (6:2)
Description: administered as a single intravenous infusion on Day 1 infused over 120 minutes
Study: NCT02600442

Intervention type: OTHER
Intervention: non interventional study
Study: NCT01497431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylselenocysteine
Description: Given PO
Study: NCT04163458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL
Description: Solution for injection in pre-filled pen, subcutaneous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MENOPUR powder and solvent for solution for injection, 75 IU
Description: Solution for injection in vials (powder and diluent), subcutaneous administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for MENOPUR solution for injection in pre-filled pen)
Description: Solution for injection in pre-filled pen, subcutaneous administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (for MENOPUR powder and solvent for solution for injection)
Description: Solution for injection in vials (powder and diluent); subcutaneous administration
Study: NCT02092844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Menopausal Insomnia (CBTMI)
Description: Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT for Menopausal Insomnia (CBTMI)
Description: Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
Study: NCT00079482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEP-701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEP-701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-dose cytarabine
Description: Chemotherapy
Study: NCT04423276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
Study: NCT00079482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)
Description: Chemotherapy
Study: NCT00607503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly.
Study: NCT04574284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor.